Health
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia – The Lancet
The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile
and induced strong humoral and cellular immune responses in participants. Further
investigation is needed of the effectiveness of this vaccine for prevention of COVID-19.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
Continue Reading
-
Noosa News22 hours agoEnsure voices are heard – Proctor
-
Noosa News24 hours agoCity of Moreton Bay claims homeless people consented to having camps thrown away
-
Business23 hours agoASX ETFs to target amidst an ageing population
-
Noosa News18 hours agoMajor crash on Gateway Motorway snarls morning commute